» COVID-19 Information


Manage your account, request prescriptions, set up appointments & more.

Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

Xeljanz A3921165


Clinical Trial Title

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Trial Status

Open to Enrollment

Start Date

November 1, 2017

Trial Type

Pediatric Rheumatology

Specific Condition

Systemic Juvenile Idiopathic Arthritis


A Randomized Double Blind Placebo Controlled Study To Evaluate Efficacy And Safety Of Cp-690,550 In Children From 2 To Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (Jia) With Active Systemic Features

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. Once 31 flares are reported the study will be completed.


Eligibility Criteria

Ages Eligible for Study: 2 Years to 17 Years (Child)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Inclusion Criteria:

  • active sJIA disease according to ILAR criteria for at least 6 weeks before screening
  • Treatment with stable doses of methotrexate (MTX) ≤25 mg/week or ≤20 mg/m2/week, whichever is lower, is permitted;
  • Treatment with a stable dose of oral prednisone ≤1 mg/kg/day up to a maximum of 30 mg/day, or equivalent, for at least 1 week before the first study drug dose is permitted.

Exclusion Criteria:

  • Previous JIA treatment with tofacitinib;
  • Current symptoms or findings of myocarditis, endocarditis or more than minimal pericardial effusion associated with sJIA. Current symptoms or findings of more than minimal pleuritis with sJIA
  • Subjects who have previously failed treatment with more than two biologic DMARDs. Note: all subjects will be allowed to have previously failed one biologic DMARD, and up to forty (40) percent of subjects will be allowed to have previously failed two biologic DMARDs provided that washout periods are respected.

IRB Number


Principal Investigator Name

Daniel Kingsbury, MD

Contact Name

Kristin Hickey



Contact Fax


Contact E-Mail


Last Updated: Wednesday, January 27, 2021 11:41:05 AM